Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL4333 Target Snapshot

Sphingosine 1-phosphate receptor 1 · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
4,566Compounds
384Assays
9Approved Drugs
5,576.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Sphingosine 1-phosphate receptor 1 shows approved-linked disease relevance led by multiple sclerosis. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt P21453. Start with multiple sclerosis, then reuse UniProt P21453 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with multiple sclerosis, then reuse UniProt P21453 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 4 linked drugs
Open source guide
Disease program
multiple sclerosis

Sphingosine 1-phosphate receptor 1 shows approved-linked disease relevance led by multiple sclerosis. 5 more disease programs remain visible in the same review block. 4 linked drugs remain visible in the same block.

Start review with multiple sclerosis because it currently carries approved-linked support. Linked drugs include OZANIMOD HYDROCHLORIDE, PONESIMOD, SIPONIMOD, SIPONIMOD FUMARIC ACID. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 4 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Sphingosine 1-phosphate receptor 1 as ChEMBL target CHEMBL4333, mapped to UniProt P21453. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Sphingosine 1-phosphate receptor 1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL4333
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
P21453
Sphingosine 1-phosphate receptor 1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Sphingosine 1-phosphate receptor 1 is the right protein anchor across sources, using UniProt P21453 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why multiple sclerosis is currently framed as approved-linked support. It currently carries 4 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameSphingosine 1-phosphate receptor 1
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtP21453
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelSphingosine 1-phosphate receptor 1
UniProt AccessionP21453
Component TypeProtein
Sequence Length382 aa

Sphingosine 1-phosphate receptor 1

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Sphingosine 1-phosphate receptor 1, mapped to UniProt P21453. Sequence length is 382 aa.

Mapped IDP21453
Review nameSphingosine 1-phosphate receptor 1
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Sphingosine 1-phosphate receptor 1 shows approved-linked disease relevance led by multiple sclerosis. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
multiple sclerosis
4 linked drugs · 4 direct · 4 efficacy
Linked drugOZANIMOD HYDROCHLORIDE
Linked drugPONESIMOD
Linked drugSIPONIMOD
Linked drugSIPONIMOD FUMARIC ACID
Approved-linked Approved
relapsing-remitting multiple sclerosis
4 linked drugs · 4 direct · 4 efficacy
Linked drugOZANIMOD HYDROCHLORIDE
Linked drugPONESIMOD
Linked drugSIPONIMOD
Linked drugSIPONIMOD FUMARIC ACID
Approved-linked Approved
ulcerative colitis
4 linked drugs · 4 direct · 4 efficacy
Linked drugETRASIMOD
Linked drugETRASIMOD ARGININE
Linked drugMOCRAVIMOD
Linked drugOZANIMOD HYDROCHLORIDE
Approved-linked Approved
secondary progressive multiple sclerosis
2 linked drugs · 2 direct · 2 efficacy
Linked drugSIPONIMOD
Linked drugSIPONIMOD FUMARIC ACID
Approved-linked Approved
chronic progressive multiple sclerosis
1 linked drug · 1 direct · 1 efficacy
Linked drugSIPONIMOD FUMARIC ACID
Late clinical Phase III
Crohn's disease
1 linked drug · 1 direct · 1 efficacy
Linked drugETRASIMOD
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with multiple sclerosis because it currently carries approved-linked support. Linked drugs include OZANIMOD HYDROCHLORIDE, PONESIMOD, SIPONIMOD, SIPONIMOD FUMARIC ACID. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasemultiple sclerosis
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

9
Approved
1
Phase III
4
Phase II
2
Phase I
Assay Mix

Activity Type Distribution

IC501,814.0
KI146.0
EC503,607.0
KD9.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL2032300 11.0 EC50 0.01 Preclinical
CHEMBL3806205 11.0 IC50 0.01 Preclinical
CHEMBL3403631 11.0 IC50 0.01 Preclinical
CHEMBL366208 10.92 EC50 0.012 Preclinical
CHEMBL2018176 10.9 EC50 0.01259 Preclinical
CHEMBL4637401 10.85 IC50 0.014 Preclinical
CHEMBL114606 10.85 IC50 0.014 Preclinical
CHEMBL2059683 10.8 EC50 0.01585 Preclinical
CHEMBL4752394 10.8 IC50 0.016 Preclinical
CHEMBL1093686 10.74 EC50 0.018 Preclinical
Distribution

pChEMBL Value Distribution

289
5.0
343
5.5
521
6.0
413
6.5
682
7.0
413
7.5
476
8.0
424
8.5
385
9.0
132
9.5
pChEMBL
Approved Drugs

Approved Drugs

ETRASIMOD
CHEMBL3358920
Approved 2023
Properties Compare Identifier
PONESIMOD
CHEMBL1096146
Approved 2021
Properties Compare Identifier
OZANIMOD
CHEMBL3707247
Approved 2020
Properties Compare Identifier
SIPONIMOD
CHEMBL2336071
Approved 2019
Properties Compare Identifier
FINGOLIMOD
CHEMBL314854
Approved 2010
Properties Compare Identifier
Assay Landscape

Assay Landscape

384
Total Assays
2,066
Tested Compounds
2
Assay Types
Functional — 193 assays, 2,066 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 139 1,461 7.9
assay format 42 500 7.1
cell membrane format 7 45 7.7
single protein format 5 60 8.4
Binding — 191 assays, 1,628 compounds
BAO Format Assays Compounds Avg pChEMBL
cell-based format 119 727 7.6
single protein format 41 465 6.3
assay format 20 394 7.3
cell membrane format 11 42 8.7

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine